Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents.
PARP inhibitors
antiangiogenic agents
bevacizumab
immunogenic cell death
platinum derivatives
taxanes
Journal
Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
02
12
2021
revised:
05
01
2022
accepted:
19
01
2022
pubmed:
20
2
2022
medline:
23
4
2022
entrez:
19
2
2022
Statut:
ppublish
Résumé
At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8
Identifiants
pubmed: 35181272
pii: S2405-8033(22)00017-6
doi: 10.1016/j.trecan.2022.01.010
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
426-444Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests J.F. and R.S. are full-time employees of Sotio Biotech. I.V. has received consulting/advisory honoraria from AstraZeneca, Clovis Oncology Inc., Carrick Therapeutics, Deciphera Pharmaceuticals, Elevar Therapeutics, Roche, Genmab, GSK, Immunogen, Jazzpharma, Mersana, Millennium Pharmaceuticals, MSD, Novocure, Octimet Oncology, Oncoinvent, Sotio, Verastem Oncology, and Zentalis; and has performed contracted research for Amgen, Genmab, Oncoinvent, and Genmab. E.G.M. has held research contracts with Roche, has received consulting/advisory honoraria from AstraZeneca and Clovis, as well as speaker honoraria from GSK, AstraZeneca, MSD, Clovis, and Roche. L.G. has held research contracts with Lytix Biopharma and Phosplatin, and has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, Sotio, The Longevity Labs, Inzen, and the Luke Heller TECPR2 Foundation. All other authors have no conflicts to declare.